NO20033921D0 - Monoamine uptake inhibitor - Google Patents

Monoamine uptake inhibitor

Info

Publication number
NO20033921D0
NO20033921D0 NO20033921A NO20033921A NO20033921D0 NO 20033921 D0 NO20033921 D0 NO 20033921D0 NO 20033921 A NO20033921 A NO 20033921A NO 20033921 A NO20033921 A NO 20033921A NO 20033921 D0 NO20033921 D0 NO 20033921D0
Authority
NO
Norway
Prior art keywords
uptake inhibitor
monoamine uptake
monoamine
inhibitor
uptake
Prior art date
Application number
NO20033921A
Other languages
Norwegian (no)
Other versions
NO20033921L (en
Inventor
Edward Louis Mattiuz
John-Michael Sauer
William Joe Wheeler
David Taiwai Wong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20033921(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20033921D0 publication Critical patent/NO20033921D0/en
Publication of NO20033921L publication Critical patent/NO20033921L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20033921A 2001-03-06 2003-09-04 Monoamine uptake inhibitor NO20033921L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
PCT/US2002/003385 WO2002070457A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Publications (2)

Publication Number Publication Date
NO20033921D0 true NO20033921D0 (en) 2003-09-04
NO20033921L NO20033921L (en) 2003-11-05

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033921A NO20033921L (en) 2001-03-06 2003-09-04 Monoamine uptake inhibitor

Country Status (35)

Country Link
US (2) US20040082666A1 (en)
EP (1) EP1379492B1 (en)
JP (1) JP2004525912A (en)
KR (1) KR20030092012A (en)
CN (1) CN1229331C (en)
AP (1) AP2003002855A0 (en)
AT (2) ATE396170T1 (en)
AU (1) AU2002245385B2 (en)
BR (1) BR0207716A (en)
CA (1) CA2440161A1 (en)
CH (1) CH695982A5 (en)
CZ (1) CZ20032380A3 (en)
DE (1) DE60226715D1 (en)
DK (1) DK200301267A (en)
EA (1) EA005768B1 (en)
EC (1) ECSP034760A (en)
EE (1) EE200300419A (en)
ES (2) ES2201942B2 (en)
FI (1) FI20031191A (en)
GB (1) GB2389851B (en)
HR (1) HRP20030710A2 (en)
HU (1) HUP0303341A3 (en)
IL (1) IL157779A0 (en)
LT (1) LT5143B (en)
LU (1) LU91038B1 (en)
LV (1) LV13119B (en)
NO (1) NO20033921L (en)
NZ (1) NZ527431A (en)
OA (1) OA12494A (en)
PL (1) PL363840A1 (en)
SE (1) SE526598C2 (en)
SK (1) SK10632003A3 (en)
TR (1) TR200705146T1 (en)
WO (1) WO2002070457A1 (en)
ZA (1) ZA200306882B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2003002855A0 (en) * 2001-03-06 2003-08-20 Lilly Co Eli Inhibitor of monoamine uptake.
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
US20070015786A1 (en) * 2003-12-12 2007-01-18 Eli Lily And Company Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (en) 2013-12-19 2016-07-07 Metrax Gmbh Device for assisting a first-aider in cardiac massage
GR1008819B (en) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Pharmaceutical composition comprising atomoxetine and method for the preparation thereof
CN107935848B (en) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 Hexaalizarin derivative and preparation method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (en) * 1978-02-24 1980-02-29 Roussel Uclaf NOVEL BENZENE PROPANAMINE DERIVATIVES AND SALTS THEREOF, PROCESS FOR THEIR PREPARATION AND APPLICATION AS MEDICAMENTS
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
CA1327795C (en) * 1987-08-14 1994-03-15 Jules Freedman Antidepressants which are aryloxy inadanamines
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
WO2000058262A1 (en) 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
WO2000061540A1 (en) 1999-04-09 2000-10-19 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
EP1395253A2 (en) * 2000-11-15 2004-03-10 Eli Lilly And Company Treatment of anxiety disorders
AP2003002855A0 (en) * 2001-03-06 2003-08-20 Lilly Co Eli Inhibitor of monoamine uptake.

Also Published As

Publication number Publication date
BR0207716A (en) 2004-03-23
CZ20032380A3 (en) 2004-03-17
ZA200306882B (en) 2004-12-03
US20050209341A1 (en) 2005-09-22
LT5143B (en) 2004-06-25
PL363840A1 (en) 2004-11-29
NZ527431A (en) 2005-05-27
CH695982A5 (en) 2006-11-15
KR20030092012A (en) 2003-12-03
ES2305221T3 (en) 2008-11-01
GB2389851A (en) 2003-12-24
EP1379492B1 (en) 2008-05-21
ES2201942A1 (en) 2004-03-16
CA2440161A1 (en) 2002-09-12
NO20033921L (en) 2003-11-05
DE60226715D1 (en) 2008-07-03
JP2004525912A (en) 2004-08-26
US7384983B2 (en) 2008-06-10
EA200300978A1 (en) 2004-02-26
GB0323169D0 (en) 2003-11-05
TR200705146T1 (en) 2008-02-21
AU2002245385B2 (en) 2007-01-18
EA005768B1 (en) 2005-06-30
CN1229331C (en) 2005-11-30
SE0302361D0 (en) 2003-09-03
US20040082666A1 (en) 2004-04-29
WO2002070457A8 (en) 2004-06-03
SE526598C2 (en) 2005-10-18
AP2003002855A0 (en) 2003-08-20
ATA90422002A (en) 2006-01-15
LT2003075A (en) 2004-03-25
ES2201942B2 (en) 2004-12-16
HUP0303341A3 (en) 2007-03-28
SE0302361L (en) 2003-09-03
AT414238B (en) 2006-10-15
LV13119B (en) 2004-06-20
DK200301267A (en) 2003-11-06
OA12494A (en) 2006-05-24
SK10632003A3 (en) 2004-06-08
ATE396170T1 (en) 2008-06-15
HRP20030710A2 (en) 2004-08-31
EP1379492A1 (en) 2004-01-14
LU91038B1 (en) 2003-09-11
EE200300419A (en) 2004-02-16
FI20031191A (en) 2003-08-25
ECSP034760A (en) 2003-10-28
IL157779A0 (en) 2004-03-28
HUP0303341A2 (en) 2004-01-28
GB2389851B (en) 2005-05-25
WO2002070457A1 (en) 2002-09-12
CN1494526A (en) 2004-05-05

Similar Documents

Publication Publication Date Title
CY2015028I1 (en) AN N-ACYLOSPHIGOSINE GLYCOSYLOTRANSFERASE INHIBITOR
DE60234125D1 (en) E INHIBITORS
PT1370553E (en) RHOQUINASE INHIBITORS
DK1425586T3 (en) Mass markers
NO20034045L (en) Metalloproteinases inhibitors
IS7291A (en) Marked kirni
DE60223654D1 (en) RESIST COMPOSITION
DE60228803D1 (en) Hammer device
FI20010780A0 (en) Improved compositions
ATE420640T1 (en) FAB I INHIBITORS
IS6915A (en) composition
NO20034032L (en) Metalloproteinases inhibitors
BR0210619A (en) composition
DE60205829T2 (en) Chain
IS7081A (en) composition
DK1272488T3 (en) Tri-aryl-substituted ethane-PDE4 inhibitors
DE60204972D1 (en) softener
NO20033921D0 (en) Monoamine uptake inhibitor
DE60229669D1 (en) X-2 INHIBITORS
DE50204245D1 (en) pawl
DE60132468D1 (en) ALEN-LANOSTEROL CYCLES INHIBITORS
ITTO20020744A0 (en) COMPOSITION
DE50214325D1 (en) One strip-overhead goal
DE60207874D1 (en) softener
DE60204623D1 (en) Inhibitor switch arrangement

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application